Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. (DYN): 12 pipeline candidates · 2 upcoming catalysts · ~20 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
20.2 months
D/E 0.25 · 0% dilution
Lead: Phase 3
12 candidates
2 upcoming, next in ~928d
6 buys · 68 sells (180d)
A transparent, data-derived signal for Dyne Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.2B
Cash
$755.5M
Quarterly Burn
$144.9M
Runway
20.2 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| DYNE-101 | Phase 1/Phase 2 |
| DYNE-244 | Preclinical |
| DYNE-245 | Preclinical |
| DYNE-251 | Phase 3 |
| DYNE-253 | Preclinical |
| DYNE-255 | Preclinical |
| FSHD program candidate | Preclinical |
| Pompe program candidate | Preclinical |
| zeleciment basivarsen | Phase 3 |
| zeleciment basivarsen (z-basivarsen) | Phase 3 |
Showing 10 of 12 candidates. Sign up for full pipeline.
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
225
Total value held
$3.00B
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 27,294,752 | $494.9M |
| vanguard capital management llc | 12,810,138 | $232.2M |
| blackrock, inc. | 11,699,870 | $212.1M |
| perceptive advisors llc | 9,337,678 | $169.3M |
| fmr llc | 8,908,980 | $161.5M |
| state street corp | 6,653,746 | $120.6M |
| fcpm iii services b.v. | 4,644,386 | $84.2M |
| tcg crossover management, llc | 4,615,144 | $83.7M |
| vanguard portfolio management llc | 4,162,041 | $75.5M |
| vestal point capital, lp | 4,000,000 | $72.5M |
Showing top 10 of 225 institutional holders of Dyne Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Dyne Therapeutics, Inc.'s pipeline?
Dyne Therapeutics, Inc. (DYN) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Dyne Therapeutics, Inc.'s lead drug candidate?
Dyne Therapeutics, Inc.'s most advanced tracked candidate is DYNE-101 (Phase 1/Phase 2) for Myotonic Dystrophy Type 1 (DM1).
What is Dyne Therapeutics, Inc.'s next catalyst?
Dyne Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Double-Blind, 48-Week Placebo-Controlled Study to Assess the Efficacy, Safety" — expected January 1, 2029.
What is Dyne Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Dyne Therapeutics, Inc. has approximately 20.2 months of cash runway.
What is Dyne Therapeutics, Inc.'s market capitalization?
Dyne Therapeutics, Inc.'s market capitalization is approximately $3.2B.
Get the full picture on Dyne Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.